ABL Bio
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
ABL Bio is a South Korean biopharmaceutical research company that develops experimental medicines targeting cancer and degenerative brain diseases, including bispecific antibodies (engineered proteins designed to attack two disease targets at once) and antibody-drug conjugates (antibodies chemically linked to cancer-killing agents).
It does not commercialize drugs directly; instead, it licenses its drug candidates and underlying platform technology to pharmaceutical partners worldwide in exchange for upfront payments and milestone fees. Listed on KOSDAQ, Korea's tech-focused stock exchange, the company operates primarily as an intellectual-property licensing business built around its proprietary bispecific-antibody platform called Grabody.
Summary is AI-generated and may contain errors · figures from DART filings
Its US subsidiary NEOK Bio handles clinical development of antibody-drug conjugate programs locally, liaising directly with the FDA and US contract research and manufacturing organizations.
ABL Bio in five facts
What does ABL Bio do?
ABL Bio is a South Korean biopharmaceutical research company that develops experimental medicines targeting cancer and degenerative brain diseases, including bispecific antibodies (engineered proteins designed to attack two disease targets at once) and antibody-drug conjugates (antibodies chemically linked to cancer-killing agents).
Where is ABL Bio listed and in which sector?
ABL Bio (Korean name: 에이비엘바이오) trades under KRX code 298380 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is ABL Bio?
Its market capitalisation was US$2B on 2026-10-21, which puts it in this site's large-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were ABL Bio's latest annual revenue and operating profit?
For fiscal year 2025, ABL Bio reported revenue of US$59.9M, an operating loss of US$30.5M and a net loss of US$28.6M, per its annual report on DART (data retrieved from DART on 2026-10-02). Revenue was up 137.6% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-10-02
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Report on large shareholdings (5% rule) (standard)Oct 16
- Report on large shareholdings (5% rule) (standard)Sep 4
- [Amended] Grant of stock optionsAug 31
- Rights offering (paid-in capital increase) decision (subsidiary)Capital raise · Mar 30
- Decision to acquire shares/equity in another company
ABL Bio disclosed an acquisition of NEOK Bio, Inc., worth US$24.9M.
M&A · Mar 30 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
ABL Bio reported consolidated results for FY2025: revenue of US$54M (+137.6% year on year), an operating loss of US$27.5M and a net loss of US$25.8M.
Earnings · Feb 6 - [Amended] Material event report (rights offering)Capital raise · Jan 16
- [Amended] Material event report (rights offering)Capital raise · Jan 9